Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zenosense, Inc. (OTC: ZENO).

Full DD Report for ZENO

You must become a subscriber to view this report.


Recent News from (OTC: ZENO)

NetworkNewsBreaks - Zenosense, Inc. (ZENO) Aims to Provide First Responders with Handheld Diagnostic Device for Cardiac Emergency
Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing MIDS Cardiac™ to give first responders a rapid, highly sensitive analysis of heart biomarkers. An article discussing the company reads: &...
Source: NetworkNewsWire
Date: May, 02 2018 14:30
Zenosense, Inc. (ZENO) Developing Handheld Diagnostic Device for Cardiac Emergency Triage
Every 43 seconds, someone in the U.S. has a heart attack Over six million patients visit U.S. emergency rooms reporting chest pain each year Chest pain symptoms can be hard to diagnose in emergencies but are vital to assessing for heart attack Zenosense’s handheld device aims t...
Source: NetworkNewsWire
Date: April, 30 2018 11:45
NetworkNewsBreaks - Zenosense, Inc. (ZENO) Targets Global POC Market with MIDS Cardiac Device
Healthcare technology company Zenosense (OTC: ZENO) is well positioned to capitalize on the projected growth in the global point-of-care (“POC”) diagnostics market, forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022 according to a rece...
Source: NetworkNewsWire
Date: April, 27 2018 10:00
Zenosense, Inc. (ZENO) Developing Game Changing Medical Nano-Magnetic Diagnostic Technology
Global Point Of Care (POC) diagnostics market projected to grow from $23.71 billion in 2017 to $38.13 billion in 2022 Patented diagnostic technology for POC devices Initial development of MIDS Cardiac™, a POC device for early and rapid cardiac biomarker detection Global cardiac...
Source: NetworkNewsWire
Date: April, 26 2018 11:15
NetworkNewsBreaks - Zenosense, Inc. (ZENO) Focuses on Development, Commercialization of Handheld POC Diagnostic Device to Rapidly Detect Heart Attack
Healthcare technology company Zenosense (OTC: ZENO) is primarily focused on the development and commercialization of MIDS Cardiac™ through the company’s joint venture ownership in MIDS Medical Limited (“MML”). An article discussing the company reads: “True, h...
Source: NetworkNewsWire
Date: April, 13 2018 15:30
Zenosense, Inc. (ZENO) is "One to Watch"
Global biomarker diagnostic testing market projected to reach $53.34 billion by 2021 from $27.95 billion in 2016 Zenosense’s device development incorporates key technology which is patent protected Technology platform could be used to test for a wide variety of common medical con...
Source: NetworkNewsWire
Date: April, 09 2018 10:30
Zenosense, Inc.: MIDS Hybrid Strip - Successful Initial Test Results
VALENCIA, SPAIN--(Marketwired - Nov 16, 2017) - Zenosense, Inc. ( OTC PINK : ZENO ) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detecti...
Source: Marketwired
Date: November, 16 2017 07:30
Zenosense, Inc. -- MIDS Hybrid Strip Detection Testing to Commence
VALENCIA, SPAIN--(Marketwired - Jul 5, 2017) - Zenosense, Inc. ( OTC PINK : ZENO ) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detectio...
Source: Marketwired
Date: July, 05 2017 07:30
Zenosense, Inc. - MIDS Hybrid Strip Detection Testing to Commence
Zenosense, Inc. - MIDS Hybrid Strip Detection Testing to Commence
Source: OTC Markets
Date: July, 05 2017 00:00
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on June 15, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SKLN 24.59% – News: STREAMWAY® System receives CE mark AMMJ 11.01% – News: Secures second client in the state of Ohio VBLT 6....
Source: NetworkNewsWire
Date: June, 15 2017 12:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-200.3750.380.380.3737,530
2018-08-170.400.380.400.37544,382
2018-08-160.39010.390.3970.38126,174
2018-08-150.37150.380.390.3618131,262
2018-08-140.370.3650.3980.36576,098

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-203,00037,5307.9936Cover
2018-08-1733,98444,38276.5716Short
2018-08-1644,51191,17448.8198Short
2018-08-1585,225131,26264.9274Short
2018-08-1448,44276,09863.6574Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZENO.


About Zenosense, Inc. (OTC: ZENO)

Logo for Zenosense, Inc. (OTC: ZENO)

Zenosense Inc. s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost effective, hand held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical Ltd. applies patent protected magnetic nanoparticle detection technology and a development team with world class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers.

 

Contact Information

 

 

Current Management

  • Carlos Jose Gil / President, CEO, CFO
  • Carlos Jose Gil /

Current Share Structure

  • Market Cap: $13,714,669 - 03/09/2018
  • Authorized: 500,000,000 - 02/05/2018
  • Issue and Outstanding: 25,397,536 - 02/05/2018
  • Float: 15,148,692 - 01/29/2018

 


Recent Filings from (OTC: ZENO)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 21 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: August, 11 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 19 2017
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: May, 19 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: April, 27 2017

 

 


Daily Technical Chart for (OTC: ZENO)

Daily Technical Chart for (OTC: ZENO)


Stay tuned for daily updates and more on (OTC: ZENO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ZENO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZENO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ZENO and does not buy, sell, or trade any shares of ZENO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/